Samjin Pharmaceutical Co. Ltd. has disclosed inhibitors of 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) and/or estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) and/or HSD17B2 (17β-HSD2). As such, they are believed to be potentially useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Pretzel Therapeutics Inc. has described DNA polymerase subunit γ-1 (POLG) modulators reported to be useful for the treatment of neurodegeneration and mitochondrial diseases.
Northridge Health Group (Hong Kong) Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) and/or tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B)-targeting moiety via a linker.
Imhotex Ltd. has disclosed desmuramylpeptide (DMP) analogues of muramyl dipeptide (MDP) acting as nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activators reported to be useful for the treatment of Crohn’s disease.
Novartis AG has described peptide-drug conjugates comprising cyclic peptides targeting HER2 (erbB2) covalently linked to a radiolabeled metal chelator through a linker reported to be useful for diagnosis and treatment of cancer.
Pfizer Inc. has divulged gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be useful for the treatment of type 2 diabetes and obesity.
Abbvie Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis and inflammatory disorders.
Nanjing Zaiming Pharmaceutical Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
RSS